Potent antibody therapeutics by design
Top Cited Papers
- 7 April 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Immunology
- Vol. 6 (5), 343-357
- https://doi.org/10.1038/nri1837
Abstract
Antibodies constitute the most rapidly growing class of human therapeutics and the second largest class of drugs after vaccines. The generation of potent antibody therapeutics, which I review here, is an iterative design process that involves the generation and optimization of antibodies to improve their clinical potential.Keywords
This publication has 100 references indexed in Scilit:
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005
- Intrabodies: production and promiseDrug Discovery Today, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Antibody humanization: a case of the ‘Emperor’s new clothes’?Immunology Today, 2000
- Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding SiteJournal of Molecular Biology, 1996
- CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar RangeJournal of Molecular Biology, 1995
- Phage antibodies: filamentous phage displaying antibody variable domainsNature, 1990
- Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coliNature, 1989
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986
- Theoretical studies of clonal selection: Minimal antibody repertoire size and reliability of self-non-self discriminationJournal of Theoretical Biology, 1979